Marjolein Peters
University of Amsterdam
GeneGenome-wide association studyInternal medicineRadiologyEndocrinologySurgeryMolecular biologyPediatricsProspective cohort studyImmunologyHaemophilia AAnemiaHaemophiliaDiseaseThrombosisPopulationRisk factorGeneticsMedicineBiologyGastroenterology
181Publications
50H-index
11.3kCitations
Publications 82
Newest
Source
Source
Source
Source
Source
#1Menno V. Huisman (Loyola University Medical Center)H-Index: 26
#2Marcel Levi (UCLH: University College London Hospitals NHS Foundation Trust)H-Index: 117
Last. Giancarlo Agnelli (University of Perugia)H-Index: 102
view all 11 authors...
Jan Wouter was born in Amsterdam and studied medicine at the University of Amsterdam, specialized in internal medicine, and defended his PhD thesis in 1971 with the subject 'Platelet functions in relation to haemostasis'. He became head of the department of thrombosis and hemostasis of the former Wilhelmina Gasthuis in Amsterdam, which later on, after the Academic Medical Center was formed, extended into the Centre for Thrombosis- Haemostasis-Atherosclerosis and Inflammation Research. In this fe...
Source
#1Alice S. van Velzen (Boston Children's Hospital)H-Index: 8
#2Corien L. Eckhardt (Boston Children's Hospital)H-Index: 11
Last. Karin Fijnvandraat (Boston Children's Hospital)H-Index: 37
view all 11 authors...
Inhibitor development is a major complication of treatment with factor VIII concentrates in nonsevere haemophilia A. It has been suggested that plasma-derived factor VIII (FVIII) concentrates elicit fewer inhibitors than recombinant FVIII concentrates, but studies in severe haemophilia A patients have shown conflicting results. We designed a case-control study to investigate the clinical and genetic risk factors for inhibitor development in nonsevere haemophilia A patients. We investigated wheth...
Source
#1Christoph Male (Medical University of Vienna)H-Index: 32
#2Anthonie W. A. Lensing (Bayer)H-Index: 45
Last. Roger BerkowH-Index: 1
view all 129 authors...
Summary Background Treatment of venous thromboembolism in children is based on data obtained in adults with little direct documentation of its efficacy and safety in children. The aim of our study was to compare the efficacy and safety of rivaroxaban versus standard anticoagulants in children with venous thromboembolism. Methods In a multicentre, parallel-group, open-label, randomised study, children (aged 0–17 years) attending 107 paediatric hospitals in 28 countries with documented acute venou...
36 CitationsSource
#1Paul Monagle (Royal Children's Hospital)H-Index: 61
#2Anthonie W. A. Lensing (Bayer)H-Index: 45
Last. Donald L. YeeH-Index: 18
view all 68 authors...
Summary Background Rivaroxaban has been shown to be efficacious for treatment of venous thromboembolism in adults, and has a reduced risk of bleeding compared with standard anticoagulants. We aimed to develop paediatric rivaroxaban regimens for the treatment of venous thromboembolism in children and adolescents. Methods In this phase 2 programme, we did three studies to evaluate rivaroxaban treatment in children younger than 6 months, aged 6 months to 5 years, and aged 6–17 years. Our studies us...
21 CitationsSource
#1Christoph Male (Medical University of Vienna)H-Index: 32
#2Anthonie W. A. Lensing (Bayer)H-Index: 45
Last. Marcela TorresH-Index: 6
view all 0 authors...
Background: Treatment of venous thromboembolism (VTE) in children is based on data obtained in adults with little direct documentation of its efficacy and safety in children. Methods: In a parallel-group open-label randomised study, 500 children aged birth to 17 years with documented acute VTE who had started heparinisation were assigned, in a 2:1 ratio, to receive bodyweight-adjusted rivaroxaban (tablets or suspension) in a 20-mg equivalent dose or standard anticoagulants. The main treatment pe...
2 CitationsSource